Opioid Withdrawal Treatment market Rising Trends, Demand and Future Scope 2025 to 2034 ...

ALK will also pay up to $320m in milestone payments to ARS in the deal, which sees the latter keep rights in the US, ...

We may not be the first wave launcher in the US, but we have plans." Natco and Mylan have also collaborated on the ...

A new focus on dermatology, ophthalmology, and gastroenterology will pave ways for many untapped opportunities that Viatris can utilize with its scale and manufacturing power. We believe Viatris is in ...

Pharmaceutical company Viatris (VTRS 13.52%) reported third-quarter 2024 financial results on Thursday, Nov. 7, that topped ...

Viatris (VTRS) stock surges after Q3 earnings beat expectations with strong revenue growth and optimistic revenue outlook for ...

Drugmaker Viatris beat Wall Street estimates for third-quarter profit and revenue on Thursday, helped by strong demand for its new generic asthma and ADHD drugs, among others, sending its shares up 2.

In a report released today, Balaji Prasad from Barclays maintained a Sell rating on Viatris (VTRS – Research Report), with a price target ...

A suit against Novartis and Vitaris by Henrietta Lacks’ estate hinges on questions about the morality and legality of using ...

Heritage is ponying up $10 million while Apotex is set to pay $39.1 million over the companies’ alleged roles in a sweeping ...

The patent office decision would allow Mylan immediately to return to the market across Europe. The generic product is now ...

Genus Pharmaceuticals (metformin, sitagliptin) (confidentiality agreement not signed, not participating) Glenmark Pharmaceuticals (metformin, sitagliptin) (confidentiality agreement not signed, not ...